ライフサイエンスコーパス: Crohn

1 Crohn's disease (CD) has been associated with an altered

2 Crohn's disease (CD) has the highest prevalence in Ashke

3 Crohn's disease (CD) is a highly heritable disease that

4 Crohn's disease (CD) is associated with a dysregulated i

5 Crohn's disease and ulcerative colitis are heterogeneous

6 Crohn's disease and ulcerative colitis are the two major

7 Crohn's disease is a chronic inflammatory condition most

8 Crohn's disease is a chronic inflammatory disease of the

9 Crohn's disease might result from a complex interplay be

10 ease (OR 0.85 [95% CI 0.74-0.98]; p < 0.03), Crohn disease (OR 0.81 [95% CI 0.70-0.94]; p < 0.005), p

11 Nine patients out of 100 (Crohn's disease- 67, ulcerative colitis- 23 and IBDU-10)

12 and clinical Crohn's disease phenotype in 69 Crohn's disease patients and 30 age- and sex-matched hea

13 ulcers in the ileum or colon, or both, and a Crohn's Disease Endoscopic Index of Severity (CDEIS) of

14 e Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with m

15 f >6 in one or more segments with ulcers), a Crohn's Disease Activity Index (CDAI) of 150-450 dependi

16 onders among patients with clinically active Crohn disease after 6 weeks of pharmacologic treatment.

17 onders among patients with clinically active Crohn disease.

18 e patients were aged 18-80 years, had active Crohn's disease of the terminal ileum, and had not respo

19 eference standard for confirmation of active Crohn disease was active terminal ileal Crohn disease ba

20 ars +/- 9) with a proved diagnosis of active Crohn disease who were scheduled to begin therapy with b

21 patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab

22 patients with moderately-to-severely active Crohn's disease.

23 pulations with moderately to severely active Crohn's disease.

24 if it was imperative to know whether active Crohn's disease was present in the small bowel.

25 he intestinal mucosa of patients with active Crohn's disease (CD).

26 sen for the treatment of persons with active Crohn's disease.

27 g clinical remission in patients with active Crohn's disease.

28 Genomics of Alzheimer's Project stage 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis,

29 milarity between plasma palmitoleic acid and Crohn's disease and find that specific fatty acids exace

30 ion false discovery rate P = .009 for AD and Crohn disease, P = 5.73 x 10-6 for AD, and 6.57 x 10-5 f

31 ry diseases such as rheumatoid arthritis and Crohn's disease.

32 rheumatoid arthritis, ulcerative colitis and Crohn disease.

33 he systematic review, ulcerative colitis and Crohn's disease needed to be reported separately.

34 matory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the whole genomes of 4,280

35 owel disease includes ulcerative colitis and Crohn's disease.

36 erum levels of C-reactive protein (CRP), and Crohn's disease activity index (CDAI) scores were measur

37 hma, atherosclerosis, pulmonary diseases and Crohn's disease as hubs and thus pointing to common infl

38 3 or 4 neutropenia, candida infections, and Crohn's disease were 0.7, 0.9, and 0.7 cases per 100 pat

39 c juvenile idiopathic arthritis, leprosy and Crohn's disease.

40 sess Regional Homogeneity (ReHo) levels, and Crohn's Disease Activity Index (CDAI) and Inflammatory B

41 fecal calprotectin, C-reactive protein, and Crohn's disease activity index scores.

42 nificantly greater than that between PSC and Crohn's disease (CD) (rG = 0.04) (P = 2.55 x 10(-15)).

43 erosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

44 l diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause significant morbidity and are

45 l diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause significant morbidity and are

46 , which includes ulcerative colitis (UC) and Crohn's disease (CD).

47 disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

48 c inflammatory bowel diseases (IBD) known as Crohn's disease and ulcerative colitis have shown strong

49 ole in chronic inflammatory diseases such as Crohn disease (CD), ulcerative colitis, psoriasis, and t

50 ontributor to inflammatory diseases, such as Crohn disease and type 2 diabetes.

51 Inflammatory bowel diseases (IBD), such as Crohn disease and ulcerative colitis, are chronic relaps

52 associated with autoimmune diseases such as Crohn disease, multiple sclerosis, and ulcerative coliti

53 barrier are associated with diseases such as Crohn's disease, colitis, and colon cancer, but mechanis

54 ence of inflammatory bowel diseases, such as Crohn's disease, in developed nations is associated with

55 ent of certain inflammatory diseases such as Crohn's disease, Wegener's granulomatosis, or sarcoidosi

56 role in the pathogenesis of autoinflammatory Crohn's disease.

57 (S727) response in patients with Montreal B2 Crohn's disease, particularly in response to IL-6 leadin

58 mmatory bowel disease, mostly shared between Crohn's disease and ulcerative colitis.

59 in patients with gastrointestinal bleeding, Crohn's disease, or celiac disease, who have had negativ

60 ity of life (HRQOL) in pediatric small bowel Crohn disease (a) change in response to infliximab thera

61 ix children with newly diagnosed small bowel Crohn disease receiving infliximab therapy were prospect

62 liximab therapy in children with small bowel Crohn disease.

63 n's disease, and ulcerative colitis) than by Crohn's disease and ulcerative colitis as currently defi

64 i-S. cerevisiae antibody levels and clinical Crohn's disease phenotype in 69 Crohn's disease patients

65 types, including ulcerative colitis, colonic Crohn's disease and ileal Crohn's disease.

66 three groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's

67 k scores to test the hypothesis that colonic Crohn's disease, ileal Crohn's disease, and ulcerative c

68 nflammatory bowel disease (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflam

69 than conventional management for controlling Crohn's disease symptoms, the risk of major adverse outc

70 opment of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis)

71 but is conserved in the sequence of deafness/Crohn's disease-associated homopolymeric glycoproteins a

72 associated with a higher risk of developing Crohn's disease (CD).

73 d pleiotropy between PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis,

74 of paediatric patients with newly diagnosed Crohn's disease at 28 sites in the USA and Canada.

75 was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plus 100-point incre

76 ars) with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6;

77 eases, including inflammatory bowel disease, Crohn's disease and rheumatoid arthritis.

78 the pathology of inflammatory bowel disease, Crohn's disease and ulcerative colitis.

79 Celiac disease, Crohn disease and ulcerative colitis are inflammatory di

80 ystemic lupus erythematosus, celiac disease, Crohn's disease, Addison's disease, primary biliary cirr

81 man disorders including Parkinson's disease, Crohn's disease, leprosy and cancer.

82 iduals with select nonpsychiatric disorders (Crohn's disease, type 1 and type 2 diabetes mellitus, mu

83 genetic risk scores (GRSs) in distinguishing Crohn's disease from healthy samples, but also serve to

84 n with inflammatory bowel disease (IBD; i.e. Crohn's disease or ulcerative colitis) and typically dev

85 bined with biomarkers in patients with early Crohn's disease results in better clinical and endoscopi

86 ts (aged 18-75 years) with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Sev

87 ease based on ileocolonoscopy or established Crohn disease and imaging features of active terminal il

88 ed 913 patients, 78 (9%) of whom experienced Crohn's disease complications.

89 atients with refractory perianal fistulizing Crohn's disease were randomly assigned to groups given i

90 ith a greater disease activity (p = 0.05 for Crohn's disease (CD), p = 0.03 for Ulcerative Colitis (U

91 mean levels of disease activity (P = .18 for Crohn's disease and P = .14 for ulcerative colitis).

92 P = 5.73 x 10-6 for AD, and 6.57 x 10-5 for Crohn disease) demonstrated the same direction of alleli

93 8% and 0.3% (odds ratio 2.04; 1.59-2.62) for Crohn's disease and 1.3% and 0.7% (odds ratio 1.75; 1.44

94 l (Randomised Evaluation of an Algorithm for Crohn's Treatment, REACT), we included community gastroe

95 and South America, including Brazil (APC for Crohn's disease +11.1% [95% CI 4.8-17.8] and APC for ulc

96 itis +14.9% [10.4-19.6]) and Taiwan (APC for Crohn's disease +4.0% [1.0-7.1] and APC for ulcerative c

97 The therapeutic armamentarium for Crohn's disease is expanding, and therefore the need to

98 had a secondary ICD-9-CM diagnosis code for Crohn disease or if the patient was not continuously enr

99 ts for quality and diagnostic confidence for Crohn disease.

100 e-smoking interactions) that affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a ca

101 gene Atg16L1 that confers increased risk for Crohn's disease in humans.

102 is useful in patients undergoing surgery for Crohn disease (CD) to avoid wide small-bowel resections.

103 00 person-years (10/100,000 person-years for Crohn's disease, 19/100,000 person-years for ulcerative

104 sis finds that gut microbiota collected from Crohn's disease patients are functionally distinct from

105 an Th17 cells, including those isolated from Crohn disease patients, and it is linked to disease, as

106 ma(+)ILC2 ex vivo in intestinal samples from Crohn's disease patients.

107 ytometry in blood and intestinal tissue from Crohn's disease patients (CD patients) and healthy contr

108 atients were 17 years old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified

109 ree clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150).

110 RTE can be used to detect fibrosis in human Crohn disease.

111 tis, which shares pathology related to human Crohn's disease (CD).

112 paediatric inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) and to

113 AGI2, MAGI3, PARD3, PTEN, and TJP1) and IBD, Crohn's disease (CD), or ulcerative colitis (UC) were in

114 is (RA) and inflammatory bowel disease (IBD; Crohn disease [CD], ulcerative colitis [UC]) and is inve

115 Ileal Crohn's disease subjects deviated most from the HP, espe

116 e colitis, colonic Crohn's disease and ileal Crohn's disease.

117 pothesis that colonic Crohn's disease, ileal Crohn's disease, and ulcerative colitis are all genetica

118 re strongly distinguished colonic from ileal Crohn's disease.

119 much better explained by three groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative

120 e inflammatory terminal or neoterminal ileal Crohn disease.

121 tissues from patients with UC, but not ileal Crohn's disease, than control tissues; levels of GATA3 c

122 Further, a subset of ileal Crohn's disease patients displayed MDR1 loss of function

123 nety subjects (45 with active terminal ileal Crohn disease and 45 without Crohn disease) underwent CT

124 tive Crohn disease was active terminal ileal Crohn disease based on ileocolonoscopy or established Cr

125 raphy for active inflammatory terminal ileal Crohn disease, despite an inferior subjective image qual

126 nd imaging features of active terminal ileal Crohn disease.

127 l ileum <40 cm), non-stricturing, ileocaecal Crohn's disease in whom conventional therapy has failed

128 UK, adults with non-stricturing, ileocaecal Crohn's disease, in whom conventional therapy has failed

129 Treatment of patients with ileocaecal Crohn's disease who have not responded to conventional t

130 e protease (MBL-MASP) functional activity in Crohn's disease patients.

131 19 might be a viable therapeutic approach in Crohn's disease.

132 ApoA1 expression, which is downregulated in Crohn's disease patients and causally linked to colitis

133 Complex perianal fistulas in Crohn's disease are challenging to treat.

134 uggest that the inflammatory milieu found in Crohn's disease could lead to or result from deregulatio

135 composition of the intestinal microbiota in Crohn's disease, but its role on skin microbiota is unkn

136 us bacteria, running under healthy mucosa in Crohn's disease.

137 es cerevisiae antibody levels is observed in Crohn's disease and this deficiency is frequently associ

138 HP prevalence in Crohn's disease (CD) patients was shown to be low compar

139 hat the genetic contribution to prognosis in Crohn's disease is largely independent of the contributi

140 ced by the dramatic therapeutic responses in Crohn's disease (CD) patients induced by chimeric anti-T

141 ur understanding of the microbiome's role in Crohn's disease by studying a unique, well-suited cohort

142 immune cells among associations stronger in Crohn's disease and in gut mucosa among associations str

143 This study supports the hypothesis that in Crohn's disease, enteric neurons and glial cells form a

144 r clinical trials of conventional therapy in Crohn's disease, HSCT resulted in clinical and endoscopi

145 Therefore, in Crohn's disease intestinal antigen taken up by lymphoid

146 non progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need

147 that are traditional for clinical trials in Crohn's disease, and identify factors that predict benef

148 ry tests were considered of limited value in Crohn's disease (CD).

149 Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, is characterized b

150 Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are co

151 r1 displayed mucosal dysfunction and induced Crohn's disease-like ileitis following transfer into Rag

152 ry rare, damaging missense variants in known Crohn's disease risk genes, suggesting that more compreh

153 18 months after resection of all macroscopic Crohn's disease.

154 Many Crohn's disease (CD) patients develop intestinal strictu

155 colitis is an experimental model that mimics Crohn's disease.

156 lcerative colitis 505 per 100 000 in Norway; Crohn's disease 322 per 100 000 in Germany) and North Am

157 is strongly associated with the aetiology of Crohn's Disease (CD) and exclusive enteral nutrition (EE

158 The aetiology of Crohn's disease is complex and may include defects in pe

159 ly our approach to a genome-wide analysis of Crohn disease, in which we replicate association with 17

160 (IBD) loci, but the genetic architecture of Crohn's disease (CD) and ulcerative colitis remain incom

161 ve tests for the diagnosis and assessment of Crohn's disease (CD) activity.

162 (sub)obstruction is a common complication of Crohn's disease (CD).

163 Early pathological descriptions of Crohn disease (CD) argued for a potential defect in lymp

164 ked to protection against the development of Crohn disease and ulcerative colitis in humans.

165 provide information about the development of Crohn's disease.

166 and Wales) who had a confirmed diagnosis of Crohn's disease and had undergone intestinal resection.

167 s were aged 18-75 years, with a diagnosis of Crohn's disease for at least 3 months, assessed as moder

168 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bow

169 we provide a physician-oriented overview of Crohn's disease in adults, ranging from epidemiology and

170 Pathogenesis of Crohn's disease (CD) involves immune and microbial dysre

171 a cytokine implicated in the pathogenesis of Crohn's disease (CD).

172 crobiota are involved in the pathogenesis of Crohn's disease, ulcerative colitis, and pouchitis.

173 rovide information about the pathogenesis of Crohn's disease.

174 ally and biologically in the pathogenesis of Crohn's disease.

175 ssed their association with 17 phenotypes of Crohn's disease (based on disease location, disease beha

176 ies reporting the incidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later

177 primary endpoint was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plu

178 e placebo group had a clinical recurrence of Crohn's disease and needed anti-inflammatory rescue trea

179 venting postoperative clinical recurrence of Crohn's disease, but only in patients who are smokers.

180 r delay postoperative clinical recurrence of Crohn's disease.

181 s that might decrease the risk of relapse of Crohn's disease (CD) after surgery, but it is unclear wh

182 ut microbial Ags in a pattern reminiscent of Crohn's disease.

183 Cs), has been linked consistently to risk of Crohn's disease (CD).

184 0.99) and a nonsignificant decreased risk of Crohn's disease (hazard ratio = 0.38, 95% confidence int

185 6L1 (rs2241880; T300A) increases the risk of Crohn's disease and it has been shown to enhance suscept

186 ebsiella strains isolated from the saliva of Crohn's disease patients can induce Th1 cell responses t

187 Studies of Crohn disease (CD), a chronic inflammatory disease of th

188 housands of control subjects from studies of Crohn disease, showing how it controls false positives,

189 (119 studies) and prevalence (69 studies) of Crohn's disease and ulcerative colitis.

190 ion, diet, and antibiotics and shed light on Crohn disease treatments.

191 Overall, 16 (72.7%) of 22 studies on Crohn's disease and 15 (83.3%) of 18 studies on ulcerati

192 lth-care costs in paediatric and adult onset Crohn's disease.

193 The risk of new-onset Crohn's disease (hazard ratio 2.19; 1.44-3.34) and ulcer

194 "The Treatment-Naive Microbiome in New-Onset Crohn's Disease," was designed to improve our understand

195 n subjects with active ulcerative colitis or Crohn's disease, implicating the loss of this barrier-pr

196 ease conditions, like Alzheimer's Disease or Crohn's Disease, associated with altered autophagy.

197 he odds of having ulcerative colitis (UC) or Crohn disease (CD) were elevated in carriers of the SLC2

198 ducted for 20 SNPs in 10 genes of paediatric Crohn's disease (CD) and for 8 SNPs in 5 genes of paedia

199 isorders including Parkinson's disease (PD), Crohn's disease, and leprosy.

200 RISK study, an inception cohort of pediatric Crohn's disease.

201 the exception of women with active perianal Crohn's disease.

202 Emerging innovative treatments for perianal Crohn disease are now available and have the promise to

203 currently the standard for imaging perianal Crohn disease.

204 amiliar with MR imaging features of perianal Crohn disease and knowledgeable about what features may

205 ith impaired quality of life from refractory Crohn disease not amenable to surgery despite treatment

206 ation) in patients with treatment-refractory Crohn's disease.

207 e been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, respectively.

208 patients with suspected, known, or relapsed Crohn's disease when ileocolonoscopy and imaging studies

209 in resting state brain activity in remissive Crohn's Disease (CD) patients after electro-acupuncture

210 ected from patients with treatment-resistant Crohn's disease who participated in a trial of ustekinum

211 iency is frequently associated with a severe Crohn's disease phenotype.

212 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necr

213 outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control al

214 ast 3 months, assessed as moderate-to-severe Crohn's disease at screening, defined as a Crohn's Disea

215 genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangit

216 All were given standard Crohn disease treatment as needed.

217 (IBD) consists of two main disease-subtypes, Crohn's disease (CD) and ulcerative colitis (UC); these

218 These results provide evidence that Crohn's disease patients have an impairment in MBL-MASP

219 rea under the curve (AUC) of scores from the Crohn's and Ulcerative Colitis Questionnaire (CUCQ) comp

220 ory score <7, and/or a decrease >/=70 in the Crohn disease activity index score compared with baselin

221 in responders (those with a decrease in the Crohn disease endoscopic index of severity score of 25-4

222 (defined as a decrease from baseline in the Crohn's Disease Activity Index [CDAI] score of >/=100 po

223 nth infection protects mice deficient in the Crohn's disease susceptibility gene Nod2 from intestinal

224 be critical for signaling downstream of the Crohn's disease susceptibility protein nucleotide-bindin

225 is demonstrated through its applications to Crohn's disease and schizophrenia using the largest stud

226 al of 57 markers with strong associations to Crohn's disease phenotypes (P < 2 x 10(-4)) were subsequ

227 a propria (LP) macrophages may contribute to Crohn's disease (CD) pathogenesis.

228 SDMB SNPs and an increased susceptibility to Crohn's disease, ulcerative colitis, and asthma.

229 , which is associated with susceptibility to Crohn's disease, was significantly correlated with an im

230 n 401 colon specimens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colo

231 us adverse event was worsening of underlying Crohn's disease.

232 cerative colitis 286 per 100 000 in the USA; Crohn's disease 319 per 100 000 in Canada).

233 We used Crohn's disease as an example and ranked the candidate d

234 tween individuals with ulcerative colitis vs Crohn's disease.

235 ophagy in intestinal defense and suggest why Crohn's disease is associated with genetic mutations tha

236 RC (222 with ulcerative colitis and 100 with Crohn's disease).

237 cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with indeterminate colitis) and p

238 eillance for neoplasia in Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age,

239 (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD]; 236 male), enrolled in Germany fro

240 13 years) newly diagnosed with IBD (43 with Crohn's disease [CD], 23 with ulcerative colitis [UC]),

241 ts (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [contro

242 119; 59 with ulcerative colitis and 60 with Crohn's disease).

243 ubphenotypes to 34,819 patients (19,713 with Crohn's disease, 14,683 with ulcerative colitis) genotyp

244 alysis included 29,838 patients (16,902 with Crohn's disease, 12,597 with ulcerative colitis).

245 tinal microbial dysbiosis is associated with Crohn's disease (CD).

246 he autophagy gene ATG16L1 is associated with Crohn's disease, an inflammatory bowel disease (IBD), an

247 bnormal biomarkers typically associated with Crohn's disease.

248 h defined formula diets, helps children with Crohn's disease and reduces inflammation and dysbiosis.

249 Granulomatous inflammation consistent with Crohn's disease was found on histopathological examinati

250 There were 312 patients diagnosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC

251 erson-years (PY)) and 12 were diagnosed with Crohn's disease (IR = 9/100,000 PY).

252 We found that study participants with Crohn's disease who received mongersen had significantly

253 The use of narcotics among patients with Crohn disease (CD) is endemic.

254 nd affected gut segments in 10 patients with Crohn disease (four women, six men; median age, 49 years

255 h colonic levels of CCDC88b in patients with Crohn disease or ulcerative colitis, identifying that ex

256 hy images were evaluated in 19 patients with Crohn disease who had strictures that underwent surgical

257 distal ileum tissues from 6-8 patients with Crohn's disease (CD) and 6-8 individuals without CD (con

258 Most patients with Crohn's disease (CD) eventually require an intestinal re

259 ced by EGCs from rats and from patients with Crohn's disease (CD), compared with controls, along with

260 patients with UC compared with patients with Crohn's disease (CD)-associated colitis or without infla

261 ese associate with outcomes of patients with Crohn's disease (CD).

262 ive structural bowel damage in patients with Crohn's disease (CD).

263 in phase II and III trials for patients with Crohn's disease (CD).

264 ease progression compared with patients with Crohn's disease (HR, 1.56; P < .001) or no IBD (HR, 1.15

265 analyses of colon tissues from patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n =

266 imens from inflamed colon of 8 patients with Crohn's disease and 8 patients with ulcerative colitis,

267 -derived stem cells (Cx601) in patients with Crohn's disease and perianal fistulas.

268 In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex periana

269 ope and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, comp

270 ng and the need for surgery in patients with Crohn's disease and ulcerative colitis have reached inco

271 me to first bowel resection in patients with Crohn's disease and ulcerative colitis.

272 apies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-

273 k stratification of paediatric patients with Crohn's disease at diagnosis, and selection of anti-TNFa

274 Most patients with Crohn's disease need an intestinal resection, but a majo

275 Up to 60% of patients with Crohn's disease need intestinal resection within the fir

276 ge psychological conditions in patients with Crohn's disease or ulcerative colitis is necessary for t

277 APCs in intestinal tissue from patients with Crohn's disease show selective failure in PD-L1 expressi

278 2008, and April 23, 2012, 240 patients with Crohn's disease were randomly assigned: 128 to mercaptop

279 r complex perianal fistulas in patients with Crohn's disease who did not respond to conventional or b

280 Most studies of patients with Crohn's disease who discontinued an immunomodulator afte

281 ture loci were mapped for 1088 patients with Crohn's disease, 361 with ulcerative colitis, 62 with IB

282 is an effective treatment for patients with Crohn's disease, but has never been adequately evaluated

283 een recommended for monitoring patients with Crohn's disease, but whether their use in treatment deci

284 In a cohort of patients with Crohn's disease, CCDC88B expression correlates positivel

285 ed studies on the use of CE in patients with Crohn's disease, celiac disease, gastrointestinal bleedi

286 In patients with Crohn's disease, perianal fistulas recur frequently, cau

287 ecrease the risk of relapse in patients with Crohn's disease.

288 iation study in two cohorts of patients with Crohn's disease.

289 y complex perianal fistulas in patients with Crohn's disease.

290 ntenance of remission in adult patients with Crohn's disease.

291 , and provide data on up to 60 patients with Crohn's disease.

292 intestinal CD4(+) T cells from patients with Crohn's disease.

293 the list of susceptibility genes shared with Crohn's disease and leprosy and implicate mucosal factor

294 Current smokers with Crohn's disease are at increased risk of surgery, while

295 Current smokers with Crohn's disease were at increased risk of intestinal res

296 erapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients

297 tive to LACC1 Ile254, cells transfected with Crohn's disease-risk LACC1 Val254 or LACC1 with mutation

298 Adult patients (>/=18 years) with Crohn's disease and treatment-refractory, draining compl

299 terminal ileal Crohn disease and 45 without Crohn disease) underwent CT enterography with a dual-sou

300 ]) in the tight control group, and worsening Crohn's disease (35 [29%] of 122 patients), arthralgia (